Progenics Pharma (PGNX) Says Data Presented at SNMMI Meeting Highlights Potential of its PSMA-Targeted Imaging Agent, PyL, in Detecting Prostate Cancer
Tweet Send to a Friend
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
